Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339248 | 0.85 | CCKBR (0.61) | CCKBRNR1H4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6332091 | 0.77 | CCKBR (0.53) | CCKBRNR1H4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6161003 | 0.76 | CCKBR (0.73) | CCKBR | |
| SCHEMBL6334704 | 0.74 | CCKBR (0.61) | CCKBRNR1H4NPC1RAB9A | |
| SCHEMBL7115482 | 0.74 | CCKBR (0.51) | CCKBRNR1H4 | |
| SCHEMBL6334200 | 0.74 | CCKBR (0.60) | CCKBRNR1H4 | |
| SCHEMBL6338361 | 0.72 | CCKBR (0.44) | CCKBRKDM4EALDH1A1 | |
| SCHEMBL6330249 | 0.71 | CCKBR (0.43) | CCKBRNR1H4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6334684 | 0.71 | CCKBR (0.61) | CCKBRNR1H4 | |
| SCHEMBL6332196 | 0.70 | CCKBR (0.52) | CCKBRNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878734-B2 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-23 | — | — | US | disclosed |
| WO-2001085723-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | GRPR, CCKBR, GIPR | CCKBR 2/4885NR1H4 79/4885NPC1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.